The Global Outpatient Oncology Infusion Market was valued at USD 2.9 billion in 2025 and is estimated to grow at a CAGR of 10.6% to reach USD 8 billion by 2035.
The market expansion is fueled by increasing preference for cost-efficient outpatient care, rising cancer prevalence, government initiatives promoting cancer awareness, and advancements in infusion technologies. Rising adoption of targeted therapies and immunotherapies, the shift toward value-based care, and telehealth-assisted infusion services are further driving demand. Lifestyle factors, obesity, and environmental influences contribute to the growing number of cancer cases, increasing the need for effective and accessible treatments. Outpatient infusion centers provide patients with a more convenient and efficient treatment model while reducing overall costs compared to hospitalization. Additionally, the integration of advanced smart infusion pumps with automated dosing, error alerts, and electronic health record (EHR) compatibility has enhanced both safety and operational efficiency, strengthening the appeal of outpatient oncology infusion services worldwide.
The infusion pumps segment held a 50.2% share in 2025. These devices, featuring portable designs and smart system integration, enhance patient comfort, allow flexible administration, and support precise dosing. Technological improvements in pumps are central to the growth of outpatient infusion services.
The targeted therapy segment accounted for a 39.5% share in 2025. These therapies act on specific molecular pathways linked to cancer and delivered through controlled infusion. Outpatient infusion centers are preferred for their administration, driving the need for advanced infusion devices and skilled personnel to monitor accurate dosing and patient response.
North America Outpatient Oncology Infusion Market held 43.1% share in 2025 and is expected to grow significantly. The region benefits from advanced healthcare infrastructure, a high number of cancer patients, and strong adoption of innovative infusion technologies. Comprehensive insurance coverage and the shift toward value-based care allow patients to access outpatient cancer treatments more affordably than in hospital settings. Adoption of smart infusion pumps and integrated EHR systems in outpatient centers enhances patient safety and operational workflow, further boosting market growth.
Key companies operating in the Global Outpatient Oncology Infusion Market include B. Braun, Baxter, Fresenius Kabi, Medtronic, MOOG, IRADIMED, Micrel, NIPRO, Teleflex, Terumo, ICU Medical, Penlon, and Becton, Dickinson and Company. Companies in the Global Outpatient Oncology Infusion Market focus on strategies such as continuous product innovation in smart infusion pumps, integration of digital health platforms, and development of user-friendly, portable devices to improve patient outcomes. Expansion into new geographic regions and partnerships with healthcare providers enhance market reach. Firms also invest in training programs for clinical staff to ensure accurate administration of therapies. Additionally, collaborations with telehealth services, EHR integration, and value-based care initiatives strengthen operational efficiency, patient safety, and long-term adoption, helping companies solidify their market foothold and maintain leadership in a competitive environment.
This product will be delivered within 2-4 business days.
The market expansion is fueled by increasing preference for cost-efficient outpatient care, rising cancer prevalence, government initiatives promoting cancer awareness, and advancements in infusion technologies. Rising adoption of targeted therapies and immunotherapies, the shift toward value-based care, and telehealth-assisted infusion services are further driving demand. Lifestyle factors, obesity, and environmental influences contribute to the growing number of cancer cases, increasing the need for effective and accessible treatments. Outpatient infusion centers provide patients with a more convenient and efficient treatment model while reducing overall costs compared to hospitalization. Additionally, the integration of advanced smart infusion pumps with automated dosing, error alerts, and electronic health record (EHR) compatibility has enhanced both safety and operational efficiency, strengthening the appeal of outpatient oncology infusion services worldwide.
The infusion pumps segment held a 50.2% share in 2025. These devices, featuring portable designs and smart system integration, enhance patient comfort, allow flexible administration, and support precise dosing. Technological improvements in pumps are central to the growth of outpatient infusion services.
The targeted therapy segment accounted for a 39.5% share in 2025. These therapies act on specific molecular pathways linked to cancer and delivered through controlled infusion. Outpatient infusion centers are preferred for their administration, driving the need for advanced infusion devices and skilled personnel to monitor accurate dosing and patient response.
North America Outpatient Oncology Infusion Market held 43.1% share in 2025 and is expected to grow significantly. The region benefits from advanced healthcare infrastructure, a high number of cancer patients, and strong adoption of innovative infusion technologies. Comprehensive insurance coverage and the shift toward value-based care allow patients to access outpatient cancer treatments more affordably than in hospital settings. Adoption of smart infusion pumps and integrated EHR systems in outpatient centers enhances patient safety and operational workflow, further boosting market growth.
Key companies operating in the Global Outpatient Oncology Infusion Market include B. Braun, Baxter, Fresenius Kabi, Medtronic, MOOG, IRADIMED, Micrel, NIPRO, Teleflex, Terumo, ICU Medical, Penlon, and Becton, Dickinson and Company. Companies in the Global Outpatient Oncology Infusion Market focus on strategies such as continuous product innovation in smart infusion pumps, integration of digital health platforms, and development of user-friendly, portable devices to improve patient outcomes. Expansion into new geographic regions and partnerships with healthcare providers enhance market reach. Firms also invest in training programs for clinical staff to ensure accurate administration of therapies. Additionally, collaborations with telehealth services, EHR integration, and value-based care initiatives strengthen operational efficiency, patient safety, and long-term adoption, helping companies solidify their market foothold and maintain leadership in a competitive environment.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Therapy, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Mode, 2021-2034 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Outpatient Oncology Infusion market report include:- B. Braun
- Baxter
- Becton, Dickinson and Company
- Fresenius Kabi
- ICU Medical
- IRADIMED
- Medtronic
- Micrel
- MOOG
- NIPRO
- Penlon
- Teleflex
- Terumo
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 135 |
| Published | December 2025 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 2.9 Billion |
| Forecasted Market Value ( USD | $ 8 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
